Clinical Trial Update: A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating the safety, tolerability and pharmacokinetics of two subcutaneous doses of Alpha1-Proteinase Inhibitor (Human) 15% in par…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• Alpha1-Proteinase Inhibitor (Human) 15% (alpha-1 proteinase inhibitor)

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Alpha1-Antitrypsin Deficiency | Phase 1, Phase 2 | Status: COMPLETED